Fusarium oxysporum pneumonia in an immunocompetent host

Southern Medical Journal

Volumn 99, Issue 6, 2006, Pages 613-616

  Gorman, Stephen R ^a   Magiorakos, Anna Pelagia ^b   Zimmerman, Sarah K ^b   Craven, Donald E ^b  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b NONE

Author keywords

Fusarium oxysporum; Pulmonary fusariosis; Voriconazole

Indexed keywords

VORICONAZOLE;

AGED; ARTICLE; CASE REPORT; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FUSARIUM OXYSPORUM; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; LUNG INFECTION; PNEUMONIA; SPECIES INVASION; SYSTEMIC DISEASE;

AGED; ANTIFUNGAL AGENTS; BRONCHOSCOPY; FEMALE; FUSARIUM; HUMANS; IMMUNOCOMPETENCE; MYCOSES; PNEUMONIA; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES;

EID: 33745712047     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000217160.63313.63     Document Type: Article

References (14)

1. Lionakis MS, Kontoyiannis DP. Fusarium infections in critically ill patients. Semin Respir Crit Care Med 2004;25:159-169.
2. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10(Suppl. 1):48-66.
3. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect. 2004;10(Suppl. 1):67-75
4. Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin N Amer 2002;16:915-933.
5. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997;90:999-1008.
6. Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003;98:315-319.
7. Arney KL, Tiernan R, Judson MA. Primary pulmonary involvement of Fusarium solani in a lung transplant recipient. Chest 1997;112:1128-1130.
8. Zach TL, Penn RG, Gnarra DJ, et al. Fusarium moniliforme pneumonia. Nebr Med J 1987;72:6-9.
9. Kurien M, Anandi V, Raman R, et al. Maxillary sinus fusariosis in immunocompetent hosts. J Laryngol Otol 1992;106:733-736.
10. Espinel-Ingroff A. Utility of mould susceptibility testing. Curr Opin Infect Dis 2003;16:527-532.
11. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002;46:3298-3300.
12. Rodriguez CA, Luján-Zilbermann J, Woodard P, et al. Successful treatment of disseminated fusariosis. Bone Marrow Transplant 2003;31:411-412.
13. Consigny S, Dhedin N, Datry A, et al. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. Clin Infect Dis 2003;37:311-313.
14. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-1131.